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Abstract
Purpose The study aimed to characterize the population phar-
macokinetics of panobinostat, a pan-deacetylase inhibitor that
has demonstrated efficacy in combination with bortezomib
and dexamethasone in patients with multiple myeloma.
Methods A nonlinear mixed-effect model was used to fit plas-
ma panobinostat concentration-time data collected from pa-
tients across 14 phase 1 and phase 2 trials following either
oral or intravenous (IV) administration. The model was used
to estimate bioavailabilities of the two oral formulations and
the effects of demographic and clinical covariates on the cen-
tral volume of distribution and clearance of panobinostat.
Results A total of 7834 samples from 581 patients were ana-
lyzed. Panobinostat pharmacokinetic parameters were best
characterized by a three-compartment model with first-order
absorption and elimination. Bioavailability was 21.4 %. Me-
dian clearance was 33.1 L/h. Interindividual variability in
clearance was 74 %. For Caucasian patients of median age
61 years, area under the curve (AUC) decreased from 104 to
88 ng· h/mL as body surface area (BSA) increased from the
first to third quartiles, 1.8 to 2.1 m2. For Caucasian patients of
median BSA 1.9 m2, AUC decreased from 102 to 95 ng· h/mL
as age increased from the first to third quartiles, 51 to 70 years.
For patients of median BSA and median age, AUC ranged
across the four race categories from 80 to 116 ng· h/mL.
Covariate analysis showed no impact on panobinostat clear-
ance and volume by patients’ sex, tumor type, kidney func-
tion, liver markers, or coadministered medications. However,
separate analyses of dedicated studies have demonstrated ef-
fects of liver impairment and CYP3A4 inhibition.
Conclusions Although covariate analyses revealed significant
effects of body size, age, and race on panobinostat pharmaco-
kinetics, these effects were minor compared to the interindi-
vidual variability and therefore not clinically relevant when
dosing panobinostat in populations similar to those studied.
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Introduction
Panobinostat is a potent pan-deacetylase inhibitor (pan-DACi)
that increases the acetylation of proteins involved in multiple
oncogenic pathways, including epigenetic aberrations, DNA
replication and repair, cell cycle progression, protein metabo-
lism and turnover, and tumor-cell survival [1]. It has shown
promising antitumor activity in several tumor types [1, 2].
Fourteen open-label phase 1 and phase 2 studies of patients
have evaluated the intravenous (IV) and oral use of single-
agent panobinostat with multiple dosing schedules in patients
with various solid and hematologic tumors [3–16]. Based on
the phase 3 PANORAMA 1 trial, panobinostat has been ap-
proved by the US Federal Drug Administation (FDA) in com-
bination with bortezomib and dexamethasone for the treat-
ment of patients with multiple myeloma who have received
at least two prior regimens, including bortezomib and an im-
munomodulatory agent.
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An exploratory IV formulation and two oral formulations
of panobinostat were developed, and the pharmacokinetics
(PK) of each formulation has been extensively evaluated in
patients during the past 10 years. Results from a phase 1 study
of IV panobinostat in patients with refractory hematologic
tumors demonstrated an approximate proportional increase
in plasma concentration and drug exposure, with an estimated
maximum concentration (Cmax, mean±SD) of 565.6±
450.9 ng/mL at the highest dose administered (14 mg/m2)
[6]. Oral panobinostat demonstrated rapid absorption (time
to Cmax <2 h), with a mean Cmax of 71 ng/mL at 60 mg [17].
Early experiences demonstrated that oral panobinostat had a
more favorable safety profile than the IV formulation. This,
combined with the added dosing convenience, has led to oral
formulation development and is the focus of the current
analysis.
Two oral formulations were developed. The initial pilot
clinical service formulation (CSF) was developed as a
monohydrate salt with dry blend formulation and was used
in two early phase 1 studies. This pilot formulation was sub-
sequently modified to improve the manufacturing process by
using a wet granulation of an anhydrous salt, which created
the final market image (FMI) formulation for mass production
and future commercialization. The in vitro dissolution profiles
for the two oral formulations are similar at pH 2.0 and 4.5.
Subsequently, ten studies, including six phase 2 studies, used
the FMI formulation.
Panobinostat is metabolized through multiple pathways—
including oxidation, reduction, hydrolysis, mono-oxygena-
tion, and glucuronidation—into approximately 40 circulating
metabolites [18]. These metabolites are devoid of inhibitory
activity toward human pan-deacetylases. The oxidative me-
tabolism of panobinostat is mediated primarily by CYP3A4
(70–98 %), with minor involvement of CYP2D6 and
CYP2C19 [14]. Panobinostat shows a plasma protein binding
of 90 %, independent of the drug concentration in plasma.
Excretion of panobinostat and its metabolites takes place to
a similar extent through the kidneys and liver, with 44.4 to
77.4% of the dose recovered in the feces and 28.6 to 51.2% of
the dose recovered in the urine [18]. The fraction excreted
unchanged in the urine was <2.5 % in patients with solid
tumors with normal renal function [19].
Although its safety, efficacy, PK, and metabolism have
been investigated in clinical trials as well as in several
in vitro studies, a thorough analysis of panobinostat popula-
tion PK has not been conducted. Population PK analyses are
crucial in drug development to identify intrinsic and extrinsic
factors among target populations that may contribute to vari-
ability in drug PK. Such variations may affect drug safety and
efficacy. A population PK model is also an important tool for
predicting exposure under new dosing regimens and as input
to PK/pharmacodynamic (PD) models to predict clinical re-
sponse. This study sought to evaluate the population PK of
panobinostat using a data set from 581 patients across 14




A population PK data set was constructed from 581 patients
with advanced hematologic and solid tumors who participated
in 14 phase 1 and phase 2 studies of panobinostat (Table 1).
Studies A2101 and A2102 used IV panobinostat, whereas all
other studies examined oral formulations of panobinostat. The
CSF was used in two of the oral panobinostat studies,
B2101and B2102, whereas the remaining studies used the
FMI formulation. The two phase 1 dose-escalation studies of
IV panobinostat used doses of 1.2 to 20 mg/m2 daily admin-
istered under various intermittent regimens. In three phase 1
dose-escalation studies, patients received oral panobinostat at
doses ranging from 10 to 80 mg/day (administered weekly on
days 1, 3, and 5; or every other week; or on days 1 and 4 every
week). In five phase 2 studies, patients with cutaneous T cell
lymphoma, chronic myeloid leukemia, and multiple myeloma
received 20mg panobinostat orally per day on days 1, 3, and 5
weekly. In three clinical pharmacology studies, patients re-
ceived oral panobinostat at 20 mg under various regimens
for study-specific purposes: in cycle 1 followed by 20 mg
per day (days 1, 3, and 5 weekly) or 45 mg (days 1 and 4
weekly) in subsequent cycles. In a phase 2 study of Hodgkin
lymphoma, patients received 40mg panobinostat on days 1, 3,
and 5 weekly.
Pharmacokinetic sampling and bioanalytical methods
PK sampling generally occurred from predose through 48 h
after each oral dose or predose through 24 h after each IV
dose. Panobinostat was precipitated from plasma samples,
evaporated to dryness, reconstituted with 10 % aqueous ace-
tonitrile (containing 0.2 % formic acid), and analyzed by liq-
uid chromatography–tandem mass spectrometry assay. The
assay was linear from 0.5 to 500 ng/mL [15], and the bias
and coefficient of variation (CV) values of the quality-
Table 1 Summary statistics of baseline categorical covariates
Covariate Distribution
Race Caucasian, 496; black, 34; Asian, 27; other, 24
Sex Male, 362; female, 219
Liver status Normal, 483; mild, 91; moderate, 6; severe, 1
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control sample results ranged from −0.7 to 0.7 % and 2.3 to
11.6 %, respectively. The lower limit of quantification of
panobinostat was 0.5 ng/mL for all studies except B2201
and B2203, for which it was 0.1 ng/mL. Values below the
lower limit of quantification (6 % of the total) were excluded.
Construction of the population pharmacokinetics data set
The data sets for modeling were prepared using SAS version
9.2. The time of panobinostat dosing or collection of blood
was computed based on the date and time when available.
When the date or time was unknown, collection times were
estimated based on time of examinations or schedule in the
protocol. Demographic information, including age, body
weight, height, sex, and race, was collected at screening and
used in the analysis. For patients with missing baseline demo-
graphics (height [n=35], body mass index [n=35], creatinine
clearance [CrCL] [n=13], and body weight [n=13]), median
values of the population were used. BSA (m2) was computed
via the Gehan–George formula as
234:94 Weight0:515  Height0:422  =10000
where weight is in kilograms and height is in centimeters.
CrCL (L/h) was computed via the Cockroft–Gault formula as
140−Ageð Þ Weight 0:85 for females½ =72
 Creatinine=88:4
where creatinine was in micromoles per liter.
The data set was validated via double programming by an
independent programmer.
Data analyses and development of the population
pharmacokinetic model
The model was developed based on the methods described by
Wahlby and colleagues [20]. Scatterplots used to visualize the
plasma concentration vs. time profile were generated using R
version 2.8.1 and SAS version 9.2. PK model building was
conducted using the first-order conditional estimation method
with INTERACTION (FOCEI) option, using the default three
significant digits for convergence, within the software pro-
gram nonlinear mixed-effect modeling (NONMEM) extended
version VI and version VII. Random interindividual variabil-
ity parameters were estimated using exponential parameteri-
zation. The exponential error models ensured that parameter
estimates were within reasonable physiological bounds; neg-
ative values were not possible. Model selection criteria were
based on both objective function values (OFVs), as generated
by NONMEM, and graphic diagnostic plots. For each model
analyzed, NONMEM calculated the minimum value of the
OFV—a statistic that, up to an additive constant, is minus
twice the log likelihood of the data. When two models are
nested and the additional parameters of the larger model are
not needed, the difference in their minimum OFV is asymp-
totically χ2 distributed, with the number of degrees of freedom
equal to the number of parameters not common to the two
models. The likelihood ratio test compared the two models
on the basis of the difference in their OFV values.
Four main diagnostic scatterplots were used in the model
selection processes: population-predicted vs. observed con-
centrations, population-weighted residuals vs. population-
predicted concentrations, individual-predicted vs. observed
concentrations, and population-weighted residuals vs. time.
In the development of the model, covariates were added into
or removed from a model based on likelihood ratio tests at a
significance level of 5 % for forward inclusion and 1 % for
backward elimination.
Development of the three-compartment model
PK data from both the IV and oral routes were fitted simulta-
neously in order to allow for estimation of the oral bioavail-
ability. Several models were explored, including two-
compartment and three-compartment models with first-order
elimination. A three-compartment model was adopted with
first-order input (in case of oral formulation) using the follow-
ing PK parameters: CL and volume of the central compart-
ment (V2), absorption rate constant (Ka), bioavailability (F),
and rate constants between the central and two peripheral
compartments: k23, k32, k24, and k42. A combined additive
and proportional residual error model was selected.
Analysis of the effects of covariates
The following covariates were investigated for their relation-
ship to panobinostat PK for CL and V2: race (Caucasian,
black, Asian, and other), weight, body mass index, BSA,
sex, age, CrCL, tumor type, and liver status, which was cate-
gorized as normal, mild, moderate, or severe according to the
following definitions (total bilirubin (TB), aspartate amino-
transferase (AST), upper limit of normal (ULN)):
Normal TB ≤ ULN; AST ≤ ULNð Þ
Mild TB ≤ ULN and AST > ULNð Þ; or ULN ≤ TB ≤ 1:5 ULNð Þð Þ
Moderate 1:5 ULN ≤ TB ≤ 3 ULNð Þ
Severe 3 ULN < TBð Þ
The effect of concomitant medications was also investigat-
ed for panobinostat CL, with the following groups included in
the analysis: drugs known to prolong QT, CYP2D6 substrates,
strong CYP3A4/5 inhibitors, CYP3A4 inducers, and sensitive
CYP3A4 substrates. The effects of the CSF vs. FMI formula-
tions on F and Ka were also analyzed.
For CL and V2, covariates (xi) and random effects (ηCL, ηV)
were incorporated into NONMEM models using the
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following method. A reference value of xi, denoted by xi0, was
selected; for continuous covariates, the median value was the
reference. Dichotomous variables were assigned a numerical
value of 0 for the reference category or 1 for the other catego-
ry. In general, categorical variables with k categories were
assigned k-1 0-or-1 variables xi,1,…, xi,k-1. Using this notation,
xi was modeled as affecting, e.g., CL as follows:
CL¼θ1⋯ zil ⋯ exp ηCLð Þ
where
zi j ¼ xi=xioð Þθi j
if xi was continuous, and
zi j ¼ θxii j
if xi was dichotomous, and
zi j ¼ θxi;1i j;1 … θxi;k−1i j;k−1
if xi was categorical with k categories.
The zij terms were tested for inclusion in models using a
forward selection procedure for entering zij. A covariate was
either included on or excluded from both CL and V2. First, the
models with exactly one zi1 and exactly one zi2 entered into the
model were fitted. The (zi1 and zi2) pair with the smallest
P<0.05 based on the likelihood ratio test was selected. Next,
the full model with all the covariates chosen at the first step
was fitted. Finally, only those covariate effects that had statis-
tically significant estimations at the 1 % level were kept in the
final model.
The random effects ηCL and ηV were modeled as normally
distributed with mean zero and with a full 2×2 covariance
matrix.
Assessment of predictive performance
To validate the final model, predictions from the model were
compared with the data using the visual predictive checks
[21]. Model development used data from 14 studies with het-
erogeneous study designs. For the validation, a subset of six
studies that had similar PK sampling designs was selected.
Another criterion for inclusion was that the study evaluated
the FMI formulation at a dose regimen of 20 mg per day on
days 1, 3, and 5 each week. From such studies, only the 20 mg
regimen was used because it is the recommended clinical dose
regimen for multiple myeloma. One study that evaluated the
CSF, B1101, was also included because this study was con-
ducted in 13 Japanese patients, and comparison of Japanese
and Western patients was of interest. For study B1101, only
observations from the 20 mg cohort were used in the
assessment.
The predictive assessment focused on day 1 (postdose:
15 min, 1–2 h, 3–4 h) and day 8 (postdose: 15 min, 1–2 h,
3–4 h) dosing. For B1101, day 15 was used instead of day 8,
which was not available; it was expected that the profile would
be similar because the half-life of panobinostat is 16 h; there-
fore, samples would be collected after steady state.
Data were simulated according to the design by which the
observed data were collected; 300 replicates of the original
data were simulated. The raw data were plotted vs. time along
with the 10th and 90th percentiles of observed values within
specified intervals; the percentiles of the simulated data within
those intervals were then superimposed.
Results
Patients
PK data were available for 7834 panobinostat concentration-
time points from 581 patients who received panobinostat in
one of 14 open-label phase 1 or phase 2 studies. Details about
the patient demographics in each of these studies are presented
in Table 1 and Fig. 1. Eighty-seven patients participated in
studies investigating IV panobinostat, whereas 494 patients
received oral panobinostat. Of these 494 patients, 106 patients
received the CSF, and 388 patients received the FMI oral
formulation.
As shown in Table 1 and Fig. 1, there were more men than
women (362 vs. 219, respectively). The median age of the PK
population was 61 years (range, 16–88 years), the median
weight was 76.4 kg (range, 41–196.4 kg), and the median
height was 170 cm (range, 143–198 cm). The vast majority
of patients were Caucasian (n=496), followed by black (n=
34) and Asian (n=27). The remaining 24 patients were clas-
sified as Bother.^
Pharmacokinetics and base model
The plasma vs. time profile of panobinostat exhibited a tri-
exponential disposition profile. This is illustrated by represen-
tative plots for the IV formulation by data from the A2101
study (Fig. 2a) and the oral formulation from the B2102 study
(Fig. 2b) [3, 10].
The results of a multiplicative model that related CL and
V2 of panobinostat to dose did not produce a significant re-
duction in the OFV. Therefore, the PK of panobinostat was
determined to be dose proportional over the dose range of 10
to 80 mg across the 14 studies.
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Following the evaluation of several structural models,
a linear three-compartment base model with first-order
absorption and combined additive and proportional re-
sidual error was found to best describe the disposition
of panobinostat. Fluxes of drug mass between the cen-
tral and peripheral compartments were parameterized in
terms of rate constants K23, K32, K24, and K42 in units
of hours−1.
Final models
Following the methodology described previously, covariate
analysis led to a final model where CL and V2 depended on
BSA, age, and race, and where absorption rate depended on
formulation.
In response to suggestions from reviewers, additional
model development was undertaken and summarized in
Table 2. A second final model was determined wherein
a formulation-dependent lag was added to the absorp-
tion process; the intercompartmental rate constants were
replaced by intercompartmental clearances and peripher-
al volumes, which were associated with multiplicative
random effects; BSA was removed from the model,
and all clearances were assumed proportional to
weight0.75 and all volumes to weight1 [22]; and age
effects were associated with the intercompartmental
clearances and peripheral volumes.
Each step of model development in Table 2 significantly
improved on the previous in terms of AIC and BIC, but the
models labeled 3 and 4 (the latter being the second final mod-
el) did not satisfy NONMEM’s default convergence criterion.
Parameter estimates from the two final models with boot-
strap confidence intervals can be found in the Supplementary
Material. With the first final model, the absolute bioavailabil-
ity of oral panobinostat was estimated as 21.4 %. The estimat-
ed median CL was 33.1 L/h for a 61-year-old Caucasian pa-
tient with BSA 1.9 m2. The estimated inter-patient variation in
CL was large, 74 %. Results were similar for the second final
model, and more generally, estimates of shared parameters
were similar between the two final models (see Supplementa-
ry Material).
Figure 3 displays simulated concentrations vs. time
for a typical patient given 20 mg of the FMI on Mon-
day, Wednesday, and Friday. The two final models pre-
dict similar profiles except for the second’s higher peak.
Supplementary Table S4 demonstrates further similarity
with respect to the predictions that account for inter-
patient variability.
Supplementary Figures S1 and S2 display goodness-of-fit
plots for the final models. The models were generally ade-
quate in describing the heterogeneous data set. Only 27
Fig. 1 Histograms and summary statistics of baseline covariates for the 581 patients in the analysis data set
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Fig. 2 Arithmetic mean (SD)
plasma panobinostat
concentration-time plots
following day 1 for intravenous
panobinostat at doses of 1.2, 2.4,
4.8, 7.2, and 9 mg/m2 (a) and oral
panobinostat at doses of 20, 30,
and 40 mg for all schedules (b).
Semilogarithmic view (data on
file)
Table 2 Model development
Model Number of parameters NONMEM objective AIC BIC
0. Base: Three-compartment, linear model with first-order absorption,
parameterized in terms of Ka, CL, V2, K23, K32, K24, K42; IIVon
CL and V2; combined additive and proportional residual error
14 33830 33858 33885
1. Final 1: Add dependence on BSA, age, and race to CL and V2;
add dependence on formulation to Ka
24 33758 33806 33851
2. Add formulation-dependent absorption lag 26 33698 33750 33799
3. Change parameterization to Ka, CL, V2, Q3, V3, Q4, V4; add IIV
to Q3, V3, Q4, V4; replace dependence of CL and V2 on BSA
with allometric dependence of all clearances and volumes on weight
30 32616 32676 32733
4. Final 2: Add dependence on age to Q3, V3, Q4, V4. 34 32591 32659 32723
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plasma panobinostat concentrations from 25 patients had pre-
dictions that exhibited a significant lack of fit (absolute value
of conditional weighted residual >4) for the first final model
(23 observations from 22 patients for the second).
Figure 4 displays the predictive checks. A total of 1393 PK
observations from patients across six studies receiving 20 mg
Monday, Wednesday, and Friday were included. The models
capture the trend in the data, although they predict more var-
iability at and beyond 24 h postdose. The second final model,
with an absorption lag, does somewhat better in the absorption
phase. Although overall numbers were small, there were no
clear inadequacies of the model with respect to the Japanese
patients.
Covariate analysis
Following the original methodology, the first final model in-
cluded BSA, age, and race as covariates affecting CL and V2.
In addition, the formulation (CSF vs. FMI) had a significant
impact on the Ka (but not on the bioavailability) of oral
panobinostat. None of the other clinical covariates investigat-
ed (route of administration, creatinine clearance at baseline,
indices of liver status, and concomitant medications) showed a
statistically significant effect on panobinostat PK. In addition,
route of administration (IV vs. oral) did not show a statistically
significant effect on CL or V2.
In the second final model, BSA was replaced by weight,
which was also applied to intercompartmental clearances and
peripheral volumes, as was age.
Table 3 summarizes the effects of covariates by showing
typical values (i.e., with random effects set to zero) of AUC,
Cmax, and the trough concentration over 48 h following a 20-
mg dose for various combinations of covariates. According to
the first final model, for Caucasian patients of median age
61 years, AUC decreased from 104 to 88 ng· h/mL as BSA
increased from the first to third quartiles, 1.8 to 2.1 m2. For
Caucasian patients of median BSA 1.9 m2, AUC decreased
from 102 to 95 ng· h/mL as age increased from the first to third
quartiles, 51 to 70 years. For patients of median BSA and
median age, AUC ranged across the four race categories from
80 to 116 ng· h/mL. The variation across covariate groups was
not large compared to unexplained variation induced by ran-
dom effects. As shown in Supplementary Table S4, when 300
Caucasian patients of median age and BSAwere simulated with
random effects, the interquartile range of AUC0-48 h was 61–
145 ng h/mL. Results were similar for the second final model.
Discussion
Panobinostat is a pan-HDAC inhibitor recently approved
by the FDA in combination with bortezomib and dexa-
methasone for the treatment of patients with multiple
myeloma who have received at least two prior regimens,
including bortezomib and an immunomodulatory agent
[Farydak® US Prescribing Information, 2015].
This is the first reported population PK study of oral and IV
panobinostat, which used 7834 PK measurements from 581
patients across 14 phase 1 and phase 2 studies. Large-scale
population PK analyses conducted during the development of
novel chemical entities are used to guide dose optimization and
administration to provide maximal benefit to the patients. The
PK behavior of panobinostat was well described by a three-
compartment model with first-order absorption and elimination,
and the model was evaluated for its predictive performance.
Body size, age at baseline, and race were statistically signif-
icant covariates on the parameters of the model. However, due
to the magnitude of these effects as compared with the unex-
plained interindividual variability, none of these covariates were
considered to be clinically relevant in the studied population.
None of the other covariates tested were found to significantly
affect CL and V2. It may be noted that in dedicated studies,
ketoconazole, a CYP3A4 inhibitor, and liver impairment were
associated with significant increases in panobinostat exposure
[14, 24]. The US prescribing information for panobinostat rec-
ommends reduced starting doses for patients with mild or mod-
erate hepatic impairment, and for patients taking strong CYP3A
inhibitors. It also recommends avoidance of strong CYP3A
inducers. That comedications and liver status were not found
significant here may have been related to study design (patients
enrolled in these trials were usually selected to have baseline
bilirubin and AST/ALT ≤1.5 and 2×ULN, respectively, and
protocols recommended to avoid the use of concomitant strong
CYP3A4 inhibitors) or due to limited power given the overall
high level of interindividual variability.























Fig. 3 Simulated concentration time curves for the two final models, for
a 61-year-old Caucasian patient with BSA 1.9 m2 (first final model) or
weight 76.4 kg (second final model) receiving 20 mg of the FMI on days
1, 3, and 5
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The current analysis also demonstrated that the absolute
bioavailability associated with the FMI formulation, which
is intended for commercialization, was 21 %. This is consis-
tent with the value derived from the geometric mean ratio of
the AUCs based on noncompartmental analysis (data on file).
The terminal half-life calculated based on the final parameter
estimates was approximately 37 h, which was similar to
values found in the control group of two independent single-
dose organ impairment studies in which PK sampling was
carried out up to 96 h postdose [23, 24]. However, there is
little accumulation with dosing every 48 h, as indicated in
Fig. 3.
Based on the results of the population PK analysis, the
starting dose of panobinostat does not need to be adjusted
for the covariates analyzed in populations similar to those
studied. Subsequent individual dose titration according to tol-
erability and efficacy should follow the drug prescribing in-
formation and study protocols as appropriate.
The model used for the population PK analysis has also
been applied as an input to a PK/PD model for platelet re-
sponse developed to better understand the relationship be-
tween thrombocytopenia, a frequent adverse event reported
with panobinostat [3], and dose and schedule [24]. The PK/
PD model was also used to support selection of the dose reg-
DAY = 1 
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Fig. 4 a–b Visual predictive checks. Data for non-Japanese patients are
indicated by gray plus signs. Data for Japanese patients are indicated by
black squares. The dashed lines connect the medians and the 10th and
90th percentiles of the raw data in the defined bins. The solid lines con-
nect the medians and the 10th and 90th percentiles of the simulations.
Dosing was 20 mg on days 1, 3, 5, and 8
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imen for the recently completed phase 3 trial of panobinostat
in combination with bortezomib and dexamethasone, which
demonstrated a significant increase in median progression-
free survival for patients who received panobinostat [18].
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